Medicinal Technologies to Launch MEnera: Revolutionary OTC Biologic for Women’s Reproductive Health by Late 2025

Medicinal Technologies, an emerging entity in biopharmaceutical advancements, has announced its plan to introduce MEnera, a novel FDA-registered over-the-counter biologic focused on improving women’s reproductive health. Scheduled for release in late 2025, MEnera is a live cell-derived, small-cell therapeutic intended to aid in hormone regulation, increase fertility, relieve menopausal symptoms, and restore menstrual regularity.

Supported by comprehensive translational research and driven by the unique Tejeda Equation—a groundbreaking scientific innovation by Dr. Sheryene Tejeda—MEnera is transforming the approach to reproductive issues such as PCOS, menopause, irregular menstrual cycles, and infertility. In contrast to traditional hormone therapies, MEnera operates at both the cellular and endocrine levels, providing clinically validated assistance for women throughout all stages of life.

A fervent spokesperson for Medicinal Technologies passionately remarked, “MEnera stands as a bold bridge between the complexities of biological intricacies and the solutions that are readily accessible,

empowering women to take proactive charge of their reproductive well-being.” Forged from the potent essence of biological cells, MEnera wields a multifaceted influence aimed at harmonizing hormone

levels, augmenting the quality of eggs, regulating menstrual cycles, and more. In addition, the combined traits of affordability and the ease of accessibility sans a prescription position MEnera as a revolutionary panacea—offering not just symptomatic relief but a holistic approach that addresses the root causes of reproductive health challenges with unparalleled efficacy.

At the core of this transformative innovation by Medicinal Technologies lies a strong commitment to  translational research, a dedication that finds its driving force from the revolutionary Tejeda Equation devloped by the esteemed scientist, Dr. Sheryene Tejeda. Through this landmark scientific breakthrough, MEnera is poised to spark a paradigm shift in the management of numerous reproductive conditions—including but not limited to PCOS, infertility, irregular menstrual patterns, and the challenges associated with menopause. What truly sets MEnera apart from conventional hormone therapies is its groundbreaking dual-action mechanism, cleverly designed to target both cellular and endocrine pathways, thus ensuring the delivery of scientifically-proven benefits tailored to women across diverse life stages with impeccable accuracy.

MEnera is scientifically formulated from active biological cells that balances hormones, improves egg quality, regulates cycles and more. Affordable and available without a prescription MEneranotably addresses underlying issues rather than merely alleviating symptoms. The U.S. market forover-the-counter medication is projected to exceed $44 million as consumers increasingly pursueevidence-based, hormone-free and non synthetic options. MEnera is leading this change, integrating cellular biology with personalized medicine.

Medicinal Technologies‘ steadfast dedication to fostering innovation across a myriad of medical domains—from gynecology and oncology to ophthalmology and endocrinology—vividly illustrates the

company’s overarching mission to provide accessible, evidence-based solutions that directly target the fundamental biological imbalances at the core of various disorders. As a true pioneer in the

biopharmaceutical landscape, Medicinal Technologies continually champions advancements in cellular

biology through the creation of over-the-counter and prescription medications, leveraging its extensive research capabilities to make meaningful contributions to the field at large.

By deftly blending visionary research undertakings with tangible real-world applications, Medicinal

Technologies remains resolute in its unwavering pursuit to uplift health outcomes and to meet the unmet therapeutic needs of individuals yearning for efficacious treatment options grounded in robust scientific principles.